NCT06885346已完成不适用
The Effectiveness of Weizmannia Coagulans BC99 in Alleviating Allergic Rhinitis in Adults and Its Impact on the Gut Microbiota
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 78
- 试验地点
- 1
- 主要终点
- The variations in intestinal flora before and after the intervention were assessed using 16S rRNA sequencing.
研究概览
简要总结
Assessing the clinical efficacy of weizmannia coagulans BC99 in alleviating allergic rhinitis symptoms, improving gut microbiota, and reducing adverse reactions in patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Voluntarily and in writing, sign an informed consent form agreeing to participate in this study; Able to complete the study as required by the trial protocol; Age between 18 and 65 years old; Meet the diagnostic criteria for allergic rhinitis established in the "Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022 Revised Edition)"; Symptoms: Presence of two or more symptoms such as sneezing, watery rhinorrhea, nasal itching, and nasal congestion, with daily symptoms lasting or accumulating for more than 1 hour, which may be accompanied by eye itching, tearing, and redness of the eyes and other ocular symptoms; Signs: Pale and edematous nasal mucosa, which may be accompanied by watery secretions.-
排除标准
- •Use of drugs affecting the gut microbiota (including antimicrobial agents, probiotics, intestinal mucosal protective agents, traditional Chinese patent medicines, etc.) for more than 1 week within 1 month prior to screening; Patients with coexisting pulmonary tuberculosis; Patients with coexisting allergic asthma; Patients with nasal polyps or severe nasal septum deviation; Patients with severe systemic diseases or malignant tumors; Individuals with congenital genetic diseases or congenital immunodeficiency diseases; Regular use of probiotics or prebiotics within 6 months prior to the screening period; Patients with severe gastrointestinal diseases (including severe diarrhea, inflammatory bowel diseases, etc.); Individuals with metabolic syndrome (including obesity, dyslipidemia, hypertension, diabetes, etc.); Patients with sinusitis, otitis media, or respiratory tract infections; Individuals allergic to any components of the probiotics used in this trial; Pregnant or lactating women or those planning to conceive in the near future; Those who discontinue the test sample or take other medications midway, making it impossible to determine efficacy or with incomplete data; Recent use of products similar to the test function, affecting the judgment of the results; Participants who cannot participate in the trial due to their own reasons; Other participants deemed ineligible by the researcher. -
结局指标
主要结局
The variations in intestinal flora before and after the intervention were assessed using 16S rRNA sequencing.
时间窗: 8 weeks
16S rRNA sequencing was performed to assess changes in the fecal microbiota of the subjects before and after the probiotic intervention, including the abundance and proportion of beneficial bacteria.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Probiotic Ameliorates Adult Allergic Rhinitis and Modulates Gut MicrobiotaAllergic RhinitisNCT06680102Wecare Probiotics Co., Ltd.78
已完成
4 期
Nasal Budesonide Efficacy on Nasal FeNO in Children With Allergic RhinitisAllergic RhinitisNCT02409563Istituto per la Ricerca e l'Innovazione Biomedica39
已完成
不适用
Demonstration of a Decongestant Effect of "Coldamaris Akut" Compared to Saline Nasal Spray.Allergic RhinitisAllergic RhinoconjunctivitisNCT04532762Marinomed Biotech AG42
已完成
不适用
Demonstration of an Anti-allergic Effect in Subjects Treated With Callergin Nasal Spray in Comparison to Untreated Subjects and Subjects Treated With Vis Alpin® Alpensalz Nasal Spray, All Suffering From Grass Pollen Induced Rhinitis/RhinoconjunctivitisAllergic RhinoconjunctivitisAllergic RhinitisNCT04531358Marinomed Biotech AG42
已完成
2 期
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe AsthmaSevere Eosinophilic AsthmaNCT02560610Chiesi Farmaceutici S.p.A.40